Holen Sie sich die Stockscreener-App
20.00
1.05%
-0.00
Schlusskurs vom Vortag:
$20.00
Offen:
$20.11
24-Stunden-Volumen:
4,218
Relative Volume:
0.25
Marktkapitalisierung:
$34.93M
Einnahmen:
$8.96M
Nettoeinkommen (Verlust:
$-9.63M
KGV:
-16.90
EPS:
-1.1831
Netto-Cashflow:
$-15.88M
1W Leistung:
-2.37%
1M Leistung:
+9.76%
6M Leistung:
+20,931%
1J Leistung:
+11,541%
1-Tages-Spanne:
$19.18
$20.11
1-Wochen-Bereich:
$18.20
$21.72
52-Wochen-Spanne:
$0.0866
$31.00
Palatin Technologies Inc. Stock (PTN) Company Profile
Firmenname
Palatin Technologies Inc.
Sektor
Branche
Telefon
609-495-2200
Adresse
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Compare PTN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
19.71 | 35.44M | 8.96M | -9.63M | -15.88M | -1.1831 |
VRTX
Vertex Pharmaceuticals Inc
|
428.72 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
718.43 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.45 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.43 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.57 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Laidlaw | Buy |
| 2025-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2015-06-05 | Bestätigt | Canaccord Genuity | Buy |
| 2015-01-12 | Bestätigt | ROTH Capital | Buy |
| 2012-05-23 | Eingeleitet | Noble Financial | Buy |
| 2007-01-23 | Eingeleitet | Next Generation | Buy |
Alle ansehen
Palatin Technologies Inc. Aktie (PTN) Neueste Nachrichten
PTN Stock Price, Quote & Chart | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill
PTN Technical Analysis | Trend, Signals & Chart Patterns | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill
AuGC reports 94,212-share stake in Palatin Technologies (PTN) - Stock Titan
Palatin Technologies (PTN) Stock: Momentum Signals (Modest Decline) 2026-04-20Social Investment Platform - Cổng thông tin điện tử tỉnh Tây Ninh
Q1 2026 Palatin Technologies Inc Earnings Call Transcript - GuruFocus
Palatin Technologies, Inc. (PTNT) - Minichart
How does Palatin Technologies (PTN) Stock react to market crashes | Price at $18.00, Down 0.11%Dividend Growth - Newser
Palatin Technologies, Inc. (PTN) - Minichart
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB) - The Globe and Mail
PTN PE Ratio & Valuation, Is PTN Overvalued - Intellectia AI
PTN Technical Analysis & Stock Price Forecast - Intellectia AI
Palatin Technologies (PTNT) Short Interest & Short Float | Updated Apr 2026 $PTNT - MarketBeat
Palatin Technologies stock faces volatility amid bremelanotide sales updates and pipeline advancemen - AD HOC NEWS
Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN) - The Globe and Mail
Palatin Technologies (PTNT) Insider Trading Activity 2026 $PTNT - MarketBeat
Palatin Technologies (PTNT) 10K Form and SEC Filings 2026 $PTNT - MarketBeat
PTN Earnings History & Surprises | EPS & Revenue Results | PALATIN TECHNOLOGIES INC (NYSEARCA:PTN) - ChartMill
PTN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Operating cash flow per share of Palatin Technologies, Inc. – LSE:0KF3 - TradingView
EBIT per share of Palatin Technologies, Inc. – LSE:0KF3 - TradingView
Dry Eye Disease Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Palatin Technologies, Novaliq, mc2 therapeutics - Barchart.com
PTN Should I Buy - Intellectia AI
Palatin Techs (PTN) Stock Analysis Report | Financials & Insights - Benzinga España
Palatin Technologies (PINK:PTNT) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
Palatin to test 2 obesity-targeting drugs for PWS in clinical trials this year - Prader-Willi Syndrome News
Palatin Technologies Q2 Earnings Call Highlights - Defense World
Palatin Technologies’ Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - The Globe and Mail
Palatin Technologies, Inc. (AMEX:PTN) Q2 2026 Earnings Call Transcript - Insider Monkey
Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - TradingView
Earnings call transcript: Palatin Technologies Q2 2026 reveals challenges By Investing.com - Investing.com South Africa
Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising Losses - GuruFocus
Earnings call transcript: Palatin Technologies Q2 2026 reveals challenges - Investing.com Australia
PTN: Strengthened cash position and advanced rare obesity pipeline with key clinical milestones ahead - TradingView
PALATIN TECHNOLOGIES INC SEC 10-Q Report - TradingView
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Malaysian Reserve
PTN | Palatin Technologies, Inc. Analyst Forecasts - Quiver Quantitative
PTN | Palatin Technologies, Inc. Insider Trading - Quiver Quantitative
Palatin Technologies Q2 revenue rises yr/yr, net loss widens - TradingView
PTN: MC4R obesity programs advance to clinical trials as cash position strengthens and net loss widens - TradingView
Palatin funds new obesity drug trials for hypothalamic obesity, PWS - Stock Titan
Palantin Technologies to enact 1-for-50 reverse stock split - MSN
Head-To-Head Contrast: Palatin Technologies (PINK:PTNT) vs. Akorn (OTCMKTS:AKRXQ) - Defense World
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Palatin Technologies (PINK:PTNT) Critical Analysis - Defense World
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - MSN
The Truth About Palatin Technologies (PTN): Tiny Biotech, Huge Hype – But Is It Worth Your Money? - AD HOC NEWS
Palatin Technologies (PINK:PTNT) Stock Price Passes Above 200-Day Moving Average – Time to Sell? - Defense World
Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN) - TradingView — Track All Markets
Finanzdaten der Palatin Technologies Inc.-Aktie (PTN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):